Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma
Current Oncology · 04.12.2024 · 31 (12) · 7770-7786
DOI: 10.3390/curroncol31120572 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 04.12.2024. Verfasst von Christine Brezden-Masley und 11 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. Hauptthemen laut MEDLINE: Adenocarcinoma, Biomarkers, Tumor, Esophageal Neoplasms, Esophagogastric Junction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Canada.
Abstract (Originalsprache)
Gastric cancer is common globally and has a generally poor prognosis with a low 5-year survival rate. Targeted therapies and immunotherapies have improved the treatment landscape, providing more options for efficacious treatment. The use of these therapies requires predictive biomarker testing to identify patients who can benefit from their use. New therapies on the horizon, such as CLDN18.2 monoclonal antibody therapy, require laboratories to implement new biomarker tests. A multidisciplinary pan-Canadian expert working group was convened to develop guidance for pathologists and oncologists on the implementation of CLDN18.2 IHC testing for gastric and gastroesophageal junction (G/GEJ) adenocarcinoma in Canada, as well as general recommendations to optimize predictive biomarker testing in G/GEJ adenocarcinoma. The expert working group recommendations highlight the importance of reflex testing for HER2, MMR and/or MSI, CLDN18, and PD-L1 in all patients at first diagnosis of G/GEJ adenocarcinoma. Testing for NTRK fusions may also be included in reflex testing or requested by the treating clinician when third-line therapy is being considered. The expert working group also made recommendations for pre-analytic, analytic, and post-analytic considerations for predictive biomarker testing in G/GEJ adenocarcinoma. Implementation of these recommendations will provide medical oncologists with accurate, timely biomarker results to use for treatment decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
- Department of Pathology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
- Laboratory Medicine Program, University Health Network, Toronto, ON M5G 2C4, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 3A7, Canada.
ORCID-Profile: Christine Brezden-Masley, Thomas Arnason, Martin Borduas, Gertruda Evaristo, Sara V Soldera, Catherine J Streutker
Förderung
- Astellas Canada
Zitieren
APA
Brezden-Masley, C., Fiset, P. O., Cheung, C. C., Arnason, T., Bateman, J., Borduas, M., Evaristo, G., Ionescu, D. N., Lim, H. J., Sheffield, B. S., Soldera, S. V., & Streutker, C. J. (2024). Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma. Current Oncology, 31(12), 7770-7786. https://doi.org/10.3390/curroncol31120572
Vancouver
Brezden-Masley C, Fiset PO, Cheung CC, Arnason T, Bateman J, Borduas M, et al. Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma. Current Oncology. 2024;31(12):7770-7786. doi:10.3390/curroncol31120572
BibTeX
@article{BrezdenMasley2024,
author = {Brezden-Masley, Christine and Fiset, Pierre O and Cheung, Carol C and Arnason, Thomas and Bateman, Justin and Borduas, Martin and Evaristo, Gertruda and Ionescu, Diana N and Lim, Howard J and Sheffield, Brandon S and Soldera, Sara V and Streutker, Catherine J},
title = {Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma},
journal = {Current Oncology},
year = {2024},
volume = {31},
number = {12},
pages = {7770--7786},
doi = {10.3390/curroncol31120572}
}
EUVIMED